QTTB241220P17500
- 5.00
- +0.55+12.36%
Q32 Bio Newsroom
Institutions Along With Private Equity Firms Who Hold Considerable Shares InQ32 Bio Inc. (NASDAQ:QTTB) Come Under Pressure; Lose 17% of Holdings Value
Positive Outlook for Q32 Bio: Buy Rating Backed by Promising Clinical Timelines and Increased Price Target
Q32 Bio Advances Clinical Trials Amidst Financial Challenges
Q32 Bio Inc Grapples With Internal Control Challenges Amid Compliance Costs
Express News | Q32 Bio Inc : Piper Sandler Raises Target Price to $85 From $60
Q32 Bio Reports Q3 EPS ($1.46), Consensus ($1.40)
Q32 Bio | 10-Q: Q3 2024 Earnings Report
Express News | Q32 Bio Q3 2024 GAAP EPS $(1.46) Misses $(1.31) Estimate, Cash And Cash Equivalents Of $89.1M As Of September 30, 2024 Expected To Provide Financial Runway Into Mid-2026
Q32 Bio: Q3 Earnings Snapshot
Q32 Bio | 8-K: Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Press Release: Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Q32 Bio 3Q Loss/Shr $1.46 >QTTB
Wells Fargo Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $95
Positive Outlook for Q32 Bio: Buy Recommendation Supported by Promising Pipeline and De-risked Lead Candidate
Raymond James Initiates Q32 Bio at Strong Buy With $90 Price Target
Oppenheimer Maintains Q32 Bio(QTTB.US) With Buy Rating, Raises Target Price to $80
Express News | Q32 Bio To Reveal Phase 1 Clinical Trial Results For Tissue-Targeted Complement Inhibitor ADX-097 At The American Society Of Nephrology Kidney Week 2024
Q32 Bio Inc. Patent Woes: Navigating the Perilous Waters of Intellectual Property Disputes
Q32 Bio Initiated at Overweight by Wells Fargo